Rajeev Kumar, D. Claassen, A. Mongan, Benjamin Hoehn, P. Lin, E. Cahir-McFarland, L. Taylor, Priya Chandra, T. Yednock, H. Kroon
{"title":"J08一项2期开放标签研究,评估明显亨廷顿舞蹈病(HD)患者或有风险患者静脉注射ANX005的安全性、耐受性、药代动力学和药效学","authors":"Rajeev Kumar, D. Claassen, A. Mongan, Benjamin Hoehn, P. Lin, E. Cahir-McFarland, L. Taylor, Priya Chandra, T. Yednock, H. Kroon","doi":"10.1136/jnnp-2022-ehdn.258","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":251913,"journal":{"name":"J: Clinical therapeutics","volume":"15 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD)\",\"authors\":\"Rajeev Kumar, D. Claassen, A. Mongan, Benjamin Hoehn, P. Lin, E. Cahir-McFarland, L. Taylor, Priya Chandra, T. Yednock, H. Kroon\",\"doi\":\"10.1136/jnnp-2022-ehdn.258\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":251913,\"journal\":{\"name\":\"J: Clinical therapeutics\",\"volume\":\"15 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"J: Clinical therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jnnp-2022-ehdn.258\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"J: Clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jnnp-2022-ehdn.258","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD)